Education
About Us
Working with TipRanks
Follow Us
Psyence Biomedical (PBM)
NASDAQ:PBM
RESEARCH TOOLSreports
PBM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.92 - $698.77
Previous CloseN/A
Volume97.84K
Average Volume (3M)112.56K
Market Cap
$2.56M
Enterprise ValueN/A
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)C$10.45K
Price to Earnings (P/E)―
Beta1.11
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.90
Shares Outstanding583,263
10 Day Avg. Volume230,844
30 Day Avg. Volume112,560
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)-0.20
Price to Sales (P/S)0.00
P/FCF Ratio-5.28K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Psyence Biomedical News
PremiumCompany Announcements
Psyence Biomedical Advances Psilocybin Drug Development as of May 2025
PremiumCompany Announcements
Psyence BioMed Implements Reverse Stock Split to Meet Nasdaq Requirements
PremiumCompany Announcements
Psyence Biomedical Transitions CRO for Psilocybin Trial in April 2025
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.31% Mutual Funds
15.16% Other Institutional Investors
99.24% Public Companies and Individual Investors
PBM FAQ
What was Psyence Biomedical’s price range in the past 12 months?
Psyence Biomedical lowest stock price was $2.92 and its highest was $698.77 in the past 12 months.
What is Psyence Biomedical’s market cap?
Psyence Biomedical’s market cap is $2.56M.
When is Psyence Biomedical’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Psyence Biomedical’s earnings last quarter?
Currently, no data Available
Is Psyence Biomedical overvalued?
According to Wall Street analysts Psyence Biomedical’s price is currently Overvalued.
Does Psyence Biomedical pay dividends?
Psyence Biomedical does not currently pay dividends.
What is Psyence Biomedical’s EPS estimate?
Psyence Biomedical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Psyence Biomedical have?
Psyence Biomedical has 583,263 shares outstanding.
What happened to Psyence Biomedical’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Psyence Biomedical?
Currently, no hedge funds are holding shares in PBM
Company Description
Psyence Biomedical
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Technical Analysis
TNF Pharmaceuticals
―
Scinai Immunotherapeutics
―
Nucana
―
Protagenic Therapeutics
―
ELEVAI Labs Inc.
―